Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

SMASH-HCM

Financiado

Cerrado

Stratification, Management, and Guidance of Hypertrophic Cardiomyopathy Patients...

Stratification, Management, and Guidance of Hypertrophic Cardiomyopathy Patients using Hybrid Digital Twin Solutions Hypertrophic cardiomyopathy (HCM) is the most common inherited heart disease (prevalence 1:200 - 1:500), manifested by thickening of cardiac walls, increasing risks of arrhythmia, and sudden cardiac death. HCM affects all ages - i... ver más

31/12/2027

TAMPERE UNIVERSITY

8M€

Presupuesto del proyecto: 8M€

Líder del proyecto

TAMPEREEN KORKEAKOULUSAATIO SR No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-01-01

HORIZON-HLTH-2023-TOOL-05-08: Pandemic preparedness and response:... Expected Outcome:This topic aims at supporting activities that are enabling or contributing to one o...

I+D +1

Cerrada hace 1 año

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

Participantes

TAMPERE UNIVERSITY

Lider

Proyectos interesantes

PID2019-104356RB-C41

Medical Technol...

Data Science

198K€ Cerrado

TwinCare-AF

Medical Technol...

Data Science

184K€ Cerrado

TIN2014-59932-JIN

Medical Technol...

Data Science

202K€ Cerrado

VHEART

Medical Technol...

Data Science

100K€ Cerrado

COMPCARDMECH

Medical Technol...

Data Science

275K€ Cerrado

PID2020-114291RB-I00

Medical Technol...

Data Science

151K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 47 meses Fecha Inicio: 2024-01-01
Fecha Fin: 2027-12-31

Líder del proyecto

TAMPEREEN KORKEAKOULUSAATIO SR No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 8M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Hypertrophic cardiomyopathy (HCM) is the most common inherited heart disease (prevalence 1:200 - 1:500), manifested by thickening of cardiac walls, increasing risks of arrhythmia, and sudden cardiac death. HCM affects all ages - it is the leading cause of death among young athletes. Comorbidities due to gene mutations include altered vascular control, and, caused by HCM, ischemia, stroke, dementia, or psychological and social difficulties. Multiple causal mutations and variations in cellular processes lead to highly diverse phenotypes and disease progression. However, HCM is still diagnosed as one single disease, leading to suboptimal care. SMASH-HCM will develop a digital-twin platform to dramatically improve HCM stratification and disease management, both for clinicians and patients. Multilevel and multiorgan dynamic biophysical and data-driven models are integrated in a three-level deep phenotyping approach designed for fast uptake into the clinical workflow. SMASH-HCM unites 8 research partners, 3 hospitals, 3 SMEs, and a global health-technology corporation in collaboration with patients to advance the state of the art in human digital-twins: including in-vitro tools, in-silico from molecular to systemic level models, structured and unstructured data analysis, explainable artificial intelligence - all integrated into a decision support solution for both healthcare professionals and patients. SMASH-HCM delivers new insights into HCM, improved patient care and guidance, validated preclinical tools, and above all, a first HCM stratification and management strategy, validated in a pilot clinical trial, and tested with end users. Thus providing a cost efficient and effective solution for this complex disease. SMASH-HCM develops a strategy towards fast regulatory approval. In reaching its goals, SMASH-HCM serves as a basis for future digital-twin platforms for other cardiac diseases integrating models and data from various scales and sources.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores